EGFR Videos

Videos

PAPILLON Trial Establishes Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

10/23/2023

Featuring Nicolas Girard, MD

Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.

Prof Nicolas Girard, MD,...

10/23/2023

Oncology

Joshua Sabari, MD, NYU Langone Health, New York, NY

Videos

Mortality on Osimertinib for Patients With EGFR-Mutant NSCLC

05/30/2023

Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.

Joshua Sabari, MD, NYU Langone...

05/30/2023

Oncology

Heather Wakelee, MD, Stanford University, Palo Alto, California

Videos

Frontline Treatment Options for Patients With EGFR-Mutated NSCLC

05/18/2023

Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.

Heather Wakelee, MD, discusses...

05/18/2023

Oncology

Helena Yu, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Videos

Combating Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Cancer

05/17/2023

At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.

At the 2023 Great Debates and...

05/17/2023

Oncology

Videos

EGFR TKIs for Curative Intent Among Patients With Early-Stage Non-Small Cell Lung Cancer

11/15/2022

Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.

Helena Yu, MD, discusses the...

11/15/2022

Oncology

Videos

EGFR: First Line, Second Line and Beyond in the Age of Osimertinib

11/07/2022

Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.

Helena Yu, MD, shares exciting...

11/07/2022

Oncology

Videos

Dr Gadgeel Discusses Pembrolizumab, Platinum-Based Chemo in EGFR/ALK-Positive NSCLC

09/29/2021

Shirish Gadgeel, MD, Henry Ford Health System, Detriot, MI, shares insight on pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-Positive non-small cell lung cancer.

Shirish Gadgeel, MD, Henry Ford...

09/29/2021

Oncology

Videos

Dr Spira Highlights Amivantamab as Promising Treatment in METex14 Mutated NSCLC

09/10/2021

Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...

Alexander Spira, MD, PhD, FACP,...

09/10/2021

Oncology

Dr Santos, Dr Raez, Dr Albrecht, Dr Socinski, Dr Heymach

Debates and Roundtables

Expert Roundtable: Are All EGFR-Sensitive Mutations Equal or Should They Be Approached Differently?

07/14/2021

In this virtual roundtable discussion, experts sat down with Oncology Learning Network to discuss EGFR sensitive mutations in patients with lung cancer.

In this virtual roundtable...

07/14/2021

Oncology

Videos

Dr Le Shares Promising Data on Poziotinib for NSCLC With EGFR or HER2 Mutations

04/28/2021

Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.

Xiuning Le, MD, PhD, discusses...

04/28/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology